ArticleEuropean heart journal2026
Gut microbe-generated metabolite trimethylamine N-oxide and risk of abdominal aortic aneurysm: a cohort study.
Article in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The TMAO Metabolic Axis in Vascular Disease: A Position Paper on Redox Mechanisms and Priorities for Clinical Translation.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
BACKGROUND AND
aimsAbdominal aortic aneurysms (AAAs) are associated with increased mortality in older adults. The gut microbe-generated metabolite trimethylamine N-oxide (TMAO) has been linked to AAA risk and promotes AAA progression in animal models. Whether circulating TMAO levels in apparently healthy older adults predict AAA development and adverse AAA outcomes remains unknown.
methodsPlasma TMAO levels were quantified using stable isotope dilution liquid chromatography-tandem mass spectrometry in 4442 community-dwelling adults (aged ≥65 years) in the Cardiovascular Health Study. Participants underwent ultrasound screening and prospective follow-up. Multivariable models assessed associations of serial TMAO levels with AAA development and incident risk for adverse AAA events, adjusting for traditional risk factors, renal function, socioeconomic status, and cardiometabolic lifestyle factors.
resultsHigher baseline TMAO levels were associated with larger infrarenal aortic diameter and increased AAA risk. Over a median 12.2-year follow-up (54 402 person-years), 79 participants experienced incident adverse AAA events (repair, rupture, or AAA-related death). Elevated TMAO levels were independently associated with higher risk of adverse AAA events, whether modelled continuously [adjusted hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.07-1.54 per doubling], by quantiles (HR for tertile 3 vs tertile 1: 2.46, 95% CI 1.32-4.59), or using a clinical threshold (≥6.2 µM; HR 1.93, 95% CI 1.25-2.99).
conclusionsIn community-based older adults, higher TMAO levels were independently associated with increased risk of AAA development and adverse AAA events. Findings support TMAO as a novel risk factor for AAA and a potential therapeutic target for AAA prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.